Premium
Meta‐Analysis of Efficacy and Safety of Apixaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Author(s) -
LU DASHENG,
LIU QIAN,
WANG KAI,
ZHANG QI,
SHAN QIJUN
Publication year - 2016
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/pace.12771
Subject(s) - medicine , atrial fibrillation , apixaban , catheter ablation , cardiology , catheter , ablation , cardiac ablation , surgery , warfarin , rivaroxaban
Background The efficacy and safety of apixaban in patients undergoing catheter ablation (CA) for atrial fibrillation (AF) are little investigated. Methods The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE were searched up to September 2015. Four literatures comparing apixaban with vitamin K antagonists (VKAs) were included. Data were pooled in Review Manager Software, using Mantel‐Haenszel methods with a fixed‐effects model. The funnel plots and Egger's test were used to examine publication bias. Heterogeneity was assessed using the I 2 test. Risk ratios (RR) and 95% confidence intervals (CI) of each study were calculated and pooled. Results No significant differences were observed in rates of total bleeding (RR = 0.91, 95% CI [0.57, 1.46], I 2 = 0.0%), thromboembolic complications (RR = 0.75, 95% CI [0.03, 18.22], I 2 = 0.0%), or total events (RR = 0.90, 95% CI [0.56, 1.44], I 2 = 0.0%) between apixaban and VKAs group. The frequency of major bleeding was similar between apixaban and VKAs group (RR = 1.34, 95% CI [0.34, 5.30], I 2 = 0.0%). Conclusion Apixaban was as effective and safe as VKAs in the periprocedural period of CA.